Hederacolchiside A1

Research use only, not for human use.

Hederacolchiside A1 shows anti-leishmanial activity it exhibits a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential.

Hederacolchiside A1 shows anti-leishmanial activity it exhibits a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential. Hederacolchiside A1 shows antiproliferation activities in three cancer cell lines with the IC50 value of 2.4 uM it exhibits a preferential cytotoxicity on a pigmented melanoma cell line. It suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway.

Hederacolchiside A1 reduces the mitochondrial membrane potential and Bcl-2 protein levels, whereas cleaved caspase-3 was higher.Hederacolchiside A1 effectively inhibits the phosphorylations of phosphatidylinositol 3 kinase (PI3K), protein kinase B (Akt), and mammalian target of rapamycin (mTOR) .

hederacolchiside A1 (3.0, 4.5, and 6.0?mg/kg, ip) can significantly inhibit the weight of tumor in an H22 xenograft model. Hederacolchiside A1 (3.25, 7.5, and 15.0?mg/kg, ig) can significantly inhibit the weight of tumor in nude mice xenograft tumor models using human breast carcinoma MCF-7 cells.

——

MAPK/ERK Signaling

MEK

MEK|ERK

——

——

106577-39-3

897.1

C47H76O16

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (111.47 mM)

C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2O[C@H]3CC[C@]4([C@H](C3(C)C)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O)C)C)C)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)O

——

(-20℃)

With Ice Pack

≥ 2 years